Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Tamoxifen
Synonyms
Therapy Description

Nolvadex (tamoxifen) is a selective estrogen receptor modulator (SERM), which decreases DNA synthesis and cell growth and is FDA approved for breast cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tamoxifen Nolvadex ICI-46474 Hormone - Anti-estrogens 29 Nolvadex (tamoxifen) is a selective estrogen receptor modulator (SERM), which decreases DNA synthesis and cell growth and is FDA approved for breast cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05659563 Phase II Tamoxifen Giredestrant Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67>=10% (EMPRESS) Recruiting FRA | ESP 0
NCT04765098 Phase II Tamoxifen Lomustine Tamoxifen Versus Lomustine After First Recurrence in GBM Patients Recruiting CAN 0
NCT02753686 Phase I Tamoxifen Exemestane Fulvestrant Letrozole Anastrozole Everolimus + Exemestane Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight) Completed CAN 0
NCT03219476 Phase II Anastrozole Letrozole Tamoxifen Exemestane Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer Active, not recruiting USA 0
NCT02936206 Phase I Tamoxifen Fulvestrant Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. Terminated USA 0
NCT04129216 Phase II Letrozole Tamoxifen Exemestane The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer Completed USA 0
NCT04134598 Phase III Tamoxifen Letrozole Anastrozole Exemestane ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged >=70 Years Early Stage Breast Cancer (EUROPA) Recruiting ITA 0
NCT03870399 Phase II Tamoxifen Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET) Completed USA | BRA 0
NCT05101564 Phase II Amcenestrant Alpelisib Infigratinib Tamoxifen Letrozole Amcenestrant + Letrozole Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer Active, not recruiting USA 0
NCT03238703 FDA approved Tamoxifen Exemestane Toremifene Anastrozole Letrozole Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Withdrawn USA 0
NCT02630693 Phase II Palbociclib Fulvestrant Tamoxifen Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer Completed CAN 0
NCT01124695 Phase II Tamoxifen Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Completed USA | CAN 1
NCT05952557 Phase III Tamoxifen Abemaciclib + Tamoxifen Abemaciclib + Exemestane Abemaciclib + Camizestrant Abemaciclib + Letrozole Abemaciclib + Anastrozole Exemestane Anastrozole Letrozole An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2) Recruiting USA | TUR | ROU | POL | NZL | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | EST | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG 19
NCT06492616 Phase III Exemestane Elacestrant Tamoxifen Letrozole Anastrozole A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT) Recruiting USA 0
NCT01027416 Phase I Tamoxifen Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients Completed USA 0
NCT03917082 Phase II Tamoxifen Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer (LALEAST) Active, not recruiting CAN 0
NCT03355157 FDA approved Exemestane + Palbociclib Tamoxifen Paclitaxel Exemestane Capecitabine Palbociclib + Tamoxifen Epirubicin Vinorelbine Fulvestrant + Palbociclib Fulvestrant Letrozole Letrozole + Palbociclib A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (PADMA) Completed DEU 0
NCT06223698 Phase III Letrozole Anastrozole Exemestane Tamoxifen Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer (SWE-Switch) Not yet recruiting SWE 0
NCT02206984 Phase I Tamoxifen Anastrozole Fulvestrant Endocrine Response in Women With Invasive Lobular Breast Cancer Completed USA 0
NCT06348134 Phase II Tamoxifen Ado-trastuzumab emtansine + Docetaxel + Pertuzumab Letrozole Ado-trastuzumab emtansine Goserelin Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery Not yet recruiting USA 0
NCT00492687 Phase II Carboplatin Temozolomide Tamoxifen Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status USA 0
NCT02311933 Phase II Z-endoxifen HCl Tamoxifen Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer Active, not recruiting USA 0
NCT05128773 Phase III Tamoxifen Amcenestrant Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity (AMEERA-6) Terminated 2
NCT05774951 Phase III Tamoxifen Exemestane Anastrozole Letrozole Camizestrant A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1) Recruiting USA | TUR | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS | ARG 18
NCT05472792 Phase II Toremifene Exemestane Tamoxifen Letrozole Anastrozole Fulvestrant Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN) (CAMERAN) Recruiting USA 0
NCT02197897 Phase II Tamoxifen Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors Completed USA 0
NCT06179303 Phase II Tamoxifen Exemestane Abemaciclib Fulvestrant Letrozole Anastrozole Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer Suspended USA 0
NCT03906669 Phase II Letrozole Tamoxifen A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. (WinPro) Recruiting AUS 0
NCT00900744 FDA approved Tamoxifen A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6 Completed USA 0
NCT02228681 Phase II Tamoxifen Medroxyprogesterone Everolimus + Letrozole Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer Completed USA 0
NCT04565054 Phase III Abemaciclib Tamoxifen Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC (ADAPTlate) Recruiting DEU 0
NCT05150652 Phase II Exemestane Tamoxifen Letrozole Anastrozole Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer Recruiting USA 0
NCT05501704 Phase II Tamoxifen Abemaciclib + Tamoxifen Abemaciclib + Anastrozole + Degarelix Anastrozole + Degarelix Anastrozole ETHAN - ET for Male BC Recruiting USA 0
NCT01272037 Phase III Anastrozole Letrozole Tamoxifen Exemestane Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Active, not recruiting USA | IRL | FRA | ESP | CAN 5
NCT04174352 Phase I Tamoxifen FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer Recruiting USA 0
NCT02764541 Phase II Palbociclib Palbociclib + Tamoxifen Letrozole Tamoxifen Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) Active, not recruiting USA 0
NCT05514054 Phase III Letrozole Anastrozole Exemestane Tamoxifen LY3484356 A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4) Recruiting USA | TUR | SVK | ROU | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG 9
NCT01293032 Phase I Tamoxifen Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer Completed USA | CAN 0
NCT06001762 Phase II Tamoxifen Exemestane Abemaciclib Anastrozole Letrozole TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer Active, not recruiting USA 0
NCT01674140 Phase III Goserelin Anastrozole Letrozole Leuprolide Everolimus Tamoxifen Exemestane S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3) Active, not recruiting USA 1
NCT02476786 Phase II Anastrozole Fulvestrant Goserelin Tamoxifen Exemestane Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score Recruiting USA 0
NCT04272801 Phase II Anastrozole Letrozole Tamoxifen Exemestane Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer (POWER) Active, not recruiting USA 0
NCT02366130 Phase II Tamoxifen Denosumab + Radium Ra 223 dichloride Fulvestrant Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer Completed USA 0
NCT02040857 Phase II Exemestane Palbociclib Tamoxifen Letrozole Anastrozole A Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer Completed USA 0
NCT05512364 Phase III Letrozole Anastrozole Exemestane Elacestrant Tamoxifen Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (TREAT ctDNA) Recruiting ITA | IRL | FRA | DEU | BEL 0
NCT02788201 Phase II Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma Completed USA 0
NCT03573648 Phase II Leuprolide Avelumab + Palbociclib + Tamoxifen Avelumab + Tamoxifen Leuprolide + Palbociclib Avelumab + Leuprolide Avelumab + Leuprolide + Palbociclib Tamoxifen Goserelin Palbociclib + Tamoxifen Avelumab + Goserelin Goserelin + Palbociclib Avelumab + Goserelin + Palbociclib Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (ImmunoADAPT) Active, not recruiting USA 0
NCT02993159 Phase II Afimoxifene Tamoxifen Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast Recruiting USA 0
NCT02269670 Phase II Tamoxifen Everolimus Megestrol acetate Letrozole Fulvestrant Anastrozole Phase II Study of Everolimus Beyond Progression Terminated USA 0


Additional content available in CKB BOOST